Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
YK-3-237 is a chalcone derivative and an activator of sirtuin 1 (SIRT1).1,2 It inhibits colchicine binding to tubulin in a concentration-dependent manner and tubulin polymerization (IC50 = 31 μM) and induces microtubule loss in A-10 cells (EC50 = 16.5 μM).1 YK-3-237 inhibits cell growth in a panel of leukemia, non-small cell lung, colon, CNS, melanoma, ovarian, renal, prostate, and breast cancer cell lines (GI50s = <0.01-20.9 μM). It inhibits tube formation by human umbilical vein endothelial cells (HUVECs) when used at a concentration of 1 μM and inhibits functional angiogenesis in isolated rat aortic rings. YK-3-237 activates SIRT1 in a concentration-dependent manner and reduces acetylation of wild-type and mutant p53 in a SIRT1-dependent manner.2 It also inhibits cell growth in panel of 9 triple-negative breast cancer (TNBC) cell lines (EC50s = 0.160-5.031 μM).
WARNING This product is not for human or veterinary use.
1. A boronic acid chalcone analog of combretastatin A-
2. Targeting mutant p53 by a SIRT1 activator YK-